AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22951192 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominoperineal extralevator resection (APER)
Number of subjects: 0
Study 22951192 — intervention group
Group type: COMPARATOR
Intervention: Standard abdominoperineal resection
Number of subjects: 0
Study 22951192 — intervention group
Group type: EXPERIMENTAL
Intervention: Extralevator abdominoperineal resection
Number of subjects: 0
Study 22951192 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional and quality-of-life-related outcomes
Number of subjects: 0
Study 19397753 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus GG (LGG) administered for 4 weeks
Number of subjects: 35
Study 19397753 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered for 4 weeks
Number of subjects: 35
Study 19397753 — intervention group
Group type: COMPARATOR
Intervention: CMA patients vs. atopic eczema only
Number of subjects: 35
Study 17977469 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA-rich fish oil (2, 4, or 6 g/d, 26% DHA, 6% EPA)
Number of subjects: 67
Study 17977469 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Sunola oil)
Number of subjects: 67
Study 16122456 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin
Number of subjects: 33
Study 16122456 — intervention group
Group type: COMPARATOR
Intervention: Control (no aprotinin)
Number of subjects: 33
Study 12351377 — intervention group
Group type: EXPERIMENTAL
Intervention: CEBPA mutations
Number of subjects: 135
Study 12351377 — intervention group
Group type: COMPARATOR
Intervention: No CEBPA mutations
Number of subjects: 135
Study 12351377 — intervention group
Group type: EXPERIMENTAL
Intervention: FLT3-ITD
Number of subjects: 135
Study 12351377 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate cytogenetic risk subgroup with CEBPA mutations
Number of subjects: 135
Study 10482212 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental presence during procedures
Number of subjects: 16
Study 8944401 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg IV cocaine hydrochloride
Number of subjects: 4
Study 8944401 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study 2006595 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine
Number of subjects: 0
Study 2006595 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine
Number of subjects: 0
Study 2006595 — intervention group
Group type: COMPARATOR
Intervention: Morphine and Lidocaine
Number of subjects: 0
Study 6963328 — intervention group
Group type: EXPERIMENTAL
Intervention: moroxydine chloride (0.04 g/kg a day)
Number of subjects: 49
Study 6963328 — intervention group
Group type: COMPARATOR
Intervention: no specific treatment (control)
Number of subjects: 49
Study 29945851 — intervention group
Group type: EXPERIMENTAL
Intervention: Veggie Van (VV) mobile produce market intervention
Number of subjects: 201
Study 28485312 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of meropenem (loading dose of 0.5 g followed by 3 g/day)
Number of subjects: 50
Study 28485312 — intervention group
Group type: COMPARATOR
Intervention: Intermittent administration of meropenem (initial dose of 1.5 g followed by 1 g every 8 hours)
Number of subjects: 50
Study 25141779 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated care group
Number of subjects: 178
Study 25141779 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 178
Study 24089227 — intervention group
Group type: EXPERIMENTAL
Intervention: Microbiological and immunological enteral nutrition (MEIN)
Number of subjects: 56
Study 24089227 — intervention group
Group type: COMPARATOR
Intervention: Ordinary enteral nutrition liquid (EN)
Number of subjects: 56
Study 22379906 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 60
Study 22379906 — intervention group
Group type: COMPARATOR
Intervention: TIVA
Number of subjects: 60
Study 19531697 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative β-blocker use
Number of subjects: 10183
Study 19531697 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 10183
Study 16855407 — intervention group
Group type: EXPERIMENTAL
Intervention: H. pylori infection assessment using C‐urea breath test and anti‐H. pylori IgG antibody titers
Number of subjects: 60
Study 16855407 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy individuals)
Number of subjects: 60
Study 16855407 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment of H. pylori infection
Number of subjects: 60
Study 12874393 — intervention group
Group type: EXPERIMENTAL
Intervention: 3,4-diaminopyridine (3,4-DAP) 20 mg
Number of subjects: 17
Study 12874393 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 11738037 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater activity in the left fusiform face area (FFA) and left dorsolateral prefrontal cortex (DLPFC) when probe faces matched the remembered face.
Number of subjects: 0
Study 11738037 — intervention group
Group type: EXPERIMENTAL
Intervention: Activity in the anterior cingulate cortex (ACC) when probe faces did not match the remembered face.
Number of subjects: 0
Study 9215513 — intervention group
Group type: EXPERIMENTAL
Intervention: Full intervention (cholesterol screening and dietary education)
Number of subjects: 635
Study 9215513 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial intervention (dietary education only)
Number of subjects: 635
Study 9215513 — intervention group
Group type: COMPARATOR
Intervention: Control (no cholesterol screening, only dietary education)
Number of subjects: 635
Study 8205303 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine (2.5 mg/day)
Number of subjects: 0
Study 8205303 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine (10 mg/day)
Number of subjects: 0
Study 8205303 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (100 mg/day)
Number of subjects: 0
Study 3300570 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride
Number of subjects: 20
Study 3300570 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 31228031 — intervention group
Group type: EXPERIMENTAL
Intervention: SHP465 mixed amphetamine salts (MAS) 12.5-75 mg
Number of subjects: 280
Study 31228031 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 280
Study 28728038 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation group treatment
Number of subjects: 178
Study 28728038 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictors of engagement
Number of subjects: 178
Study 28728038 — intervention group
Group type: EXPERIMENTAL
Intervention: Full multivariable logistic regression model
Number of subjects: 178
Study 25978378 — intervention group
Group type: EXPERIMENTAL
Intervention: Sound of running water (SRW) played by a mobile application
Number of subjects: 18
Study 25978378 — intervention group
Group type: COMPARATOR
Intervention: No sound of running water (without SRW)
Number of subjects: 18
Study 23273106 — intervention group
Group type: EXPERIMENTAL
Intervention: delta‐9‐tetrahydrocannabinol (THC)
Number of subjects: 0
Study 21654553 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive case-based module
Number of subjects: 43
Study 21654553 — intervention group
Group type: COMPARATOR
Intervention: Traditional textbook-style module
Number of subjects: 43
Study 18635335 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular repair using the Powerlink endovascular graft
Number of subjects: 258
Study 18635335 — intervention group
Group type: COMPARATOR
Intervention: Conventional open surgery
Number of subjects: 258
Study 16234990 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular lavage with 5 l of saline
Number of subjects: 142
Study 16234990 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular lavage with 3 l of saline
Number of subjects: 142
Study 16234990 — intervention group
Group type: COMPARATOR
Intervention: Arthrocentesis
Number of subjects: 142
Study 12973821 — intervention group
Group type: EXPERIMENTAL
Intervention: Salurin (Julphar, UAE)
Number of subjects: 24
Study 12973821 — intervention group
Group type: COMPARATOR
Intervention: Lasix (Hoechst AG, Germany)
Number of subjects: 24
Study 10993032 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibolone (n = 32)
Number of subjects: 113
Study 10993032 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated estrogens plus sequential norgestrel (CEEP) (n = 31)
Number of subjects: 113
Study 10993032 — intervention group
Group type: COMPARATOR
Intervention: No treatment control (n = 50)
Number of subjects: 113
Study 9298264 — intervention group
Group type: EXPERIMENTAL
Intervention: Who Do You Tell program (N = 117)
Number of subjects: 231
Study 9298264 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control condition (N = 114)
Number of subjects: 231
Study 7504880 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone 200 mg/day (n = 115)
Number of subjects: 368
Study 7504880 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol 100 to 200 mg/day (n = 130)
Number of subjects: 368
Study 7504880 — intervention group
Group type: COMPARATOR
Intervention: No antiarrhythmic therapy (n = 123)
Number of subjects: 368
Study 7504880 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 368
Study 7504880 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 368
Study 3517508 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (200 micrograms/L)
Number of subjects: 48
Study 3517508 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 30551120 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine colostrum supplementation
Number of subjects: 70
Study 29665432 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity continuous exercise (MCE)
Number of subjects: 18
Study 29665432 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity interval exercise (HIIE)
Number of subjects: 18
Study 29665432 — intervention group
Group type: COMPARATOR
Intervention: Seated rest condition (Control)
Number of subjects: 18
Study 27307415 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity atorvastatin (80 mg/d before PCI and 40 mg/d thereafter for 1 year)
Number of subjects: 798
Study 27307415 — intervention group
Group type: COMPARATOR
Intervention: Moderate-intensity atorvastatin (20 mg/d for 1 year)
Number of subjects: 798
Study 24709487 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel (75 mg/m², IV) + Vandetanib (100 mg daily, PO)
Number of subjects: 131
Study 24709487 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel (75 mg/m², IV)
Number of subjects: 131
Study 24709487 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel followed by Vandetanib (D → V)
Number of subjects: 131
Study 24709487 — intervention group
Group type: EXPERIMENTAL
Intervention: Crossover Vandetanib response
Number of subjects: 131
Study 24709487 — intervention group
Group type: EXPERIMENTAL
Intervention: Crossover Vandetanib (D → V)
Number of subjects: 131
Study 22680916 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous femoral nerve analgesia (CFA), ropivacaine 25 mg bolus and 5 mg/h infusion for 24 hours after surgery.
Number of subjects: 62
Study 22680916 — intervention group
Group type: COMPARATOR
Intervention: Oral analgesics (control group).
Number of subjects: 62
Study 22680916 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous femoral nerve analgesia (CFA).
Number of subjects: 62
Study 20228403 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan (up to 160 mg daily)
Number of subjects: 9306
Study 20228403 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9306
Study 17655723 — intervention group
Group type: EXPERIMENTAL
Intervention: Bulkamid (hydrogel cross‐linked with polyacrylamide)
Number of subjects: 10
Study 17655723 — intervention group
Group type: EXPERIMENTAL
Intervention: Permacol (porcine dermal collagen)
Number of subjects: 10
Study 17655723 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-week bowel diary and SF-36 forms
Number of subjects: 10
Study 15953083 — intervention group
Group type: EXPERIMENTAL
Intervention: Moisturizing cream applied twice daily for 6 weeks
Number of subjects: 17
Study 15953083 — intervention group
Group type: COMPARATOR
Intervention: Control site (left leg, no treatment)
Number of subjects: 17
Study 15953083 — intervention group
Group type: EXPERIMENTAL
Intervention: Moisturizing cream
Number of subjects: 17
Study 12745799 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐min period of ischemic preconditioning before cardioplegia
Number of subjects: 30
Study 12745799 — intervention group
Group type: COMPARATOR
Intervention: Conventional normothermic retrograde blood cardioplegia
Number of subjects: 30
Study 12745799 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 30
Study 10578982 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic cytology
Number of subjects: 228
Study 10578982 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic biopsy
Number of subjects: 228
Study 10578982 — intervention group
Group type: EXPERIMENTAL
Intervention: Antitubercular treatment
Number of subjects: 228
Study 10578982 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Number of subjects: 228
Study 9772616 — intervention group
Group type: EXPERIMENTAL
Intervention: Xilixin granule (XLXG) combined with radiotherapy
Number of subjects: 36
Study 9772616 — intervention group
Group type: COMPARATOR
Intervention: Zhenqi Fuzheng granule combined with radiotherapy
Number of subjects: 36
Study 8340983 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation (500 mg/d as calcium citrate malate)
Number of subjects: 94
Study 8340983 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study 3729636 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual oxygen prescriptions
Number of subjects: 12
Study 3729636 — intervention group
Group type: COMPARATOR
Intervention: Room air (through nasal prongs)
Number of subjects: 12
Study 31256309 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure-controlled mask ventilation at 12 cmH2O (P12)
Number of subjects: 75
Study 31256309 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure-controlled mask ventilation at 15 cmH2O (P15)
Number of subjects: 75
Study 31256309 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure-controlled mask ventilation at 20 cmH2O (P20)
Number of subjects: 75
Study 29877615 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation (RFA)
Number of subjects: 440
Study 29877615 — intervention group
Group type: COMPARATOR
Intervention: Stereotactic body radiotherapy (SBRT)
Number of subjects: 440
Study 29877615 — intervention group
Group type: COMPARATOR
Intervention: Both RFA and SBRT
Number of subjects: 440
Study 26742708 — intervention group
Group type: EXPERIMENTAL
Intervention: (131)I‐MIBG (444 or 666 MBq/kg) plus arsenic trioxide (0.15 or 0.25 mg/m(2))
Number of subjects: 21
Study 26742708 — intervention group
Group type: COMPARATOR
Intervention: (131)I‐MIBG alone (historical data)
Number of subjects: 21
Study 25899875 — intervention group
Group type: EXPERIMENTAL
Intervention: Photon irradiation (25 × 2Gy)
Number of subjects: 72
Study 25899875 — intervention group
Group type: COMPARATOR
Intervention: Electron beam irradiation (13 × 3Gy)
Number of subjects: 72
Study 25899875 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of photon vs electron irradiation
Number of subjects: 72
Study 25899875 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment efficacy
Number of subjects: 72
Study 22516569 — intervention group
Group type: EXPERIMENTAL
Intervention: Milch technique
Number of subjects: 60
Study 22516569 — intervention group
Group type: COMPARATOR
Intervention: Stimson technique
Number of subjects: 60
Study 20861520 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional facemask (CM)
Number of subjects: 10
Study 20861520 — intervention group
Group type: COMPARATOR
Intervention: Respiratory snorkel (RS)
Number of subjects: 10
Study 18165839 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Performance Scale value (CPS) superior to 3 (impaired)
Number of subjects: 4010
Study 18165839 — intervention group
Group type: COMPARATOR
Intervention: Scoring more than 3 on the CPS (disabled)
Number of subjects: 4010
Study 18165839 — intervention group
Group type: EXPERIMENTAL
Intervention: Less than one meal/day, reduced appetite, malnutrition, reduced social activity, experiencing a flare-up of a recurrent or chronic problem, and hospitalisation
Number of subjects: 4010
Study 16415699 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (maximum dose of 200 mg/d)
Number of subjects: 328
Study 16415699 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 328
Study 16415699 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 328
Study 12556405 — intervention group
Group type: EXPERIMENTAL
Intervention: BQ-123 (ET(A) receptor antagonist)
Number of subjects: 12
Study 12556405 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (angiotensin converting enzyme inhibitor)
Number of subjects: 12
Study 12556405 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 10096581 — intervention group
Group type: EXPERIMENTAL
Intervention: Tat toxoid
Number of subjects: 5
Study 7852062 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual intervention
Number of subjects: 255
Study 7852062 — intervention group
Group type: EXPERIMENTAL
Intervention: Group intervention
Number of subjects: 255
Study 7852062 — intervention group
Group type: EXPERIMENTAL
Intervention: Written intervention
Number of subjects: 255
Study 7852062 — intervention group
Group type: COMPARATOR
Intervention: No Intervention
Number of subjects: 255
Study 2639596 — intervention group
Group type: EXPERIMENTAL
Intervention: FIBS preparation
Number of subjects: 60
Study 2639596 — intervention group
Group type: COMPARATOR
Intervention: Typical treatment for uveitis
Number of subjects: 60
Study 956557 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline
Number of subjects: 0
Study 956557 — intervention group
Group type: EXPERIMENTAL
Intervention: Ephedrine
Number of subjects: 0
Study 29801187 — intervention group
Group type: EXPERIMENTAL
Intervention: Work-Related Medical Rehabilitation (WMR)
Number of subjects: 476
Study 28494646 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic hematopoietic stem cell transplantation (allo-HSCT)
Number of subjects: 182
Study 28494646 — intervention group
Group type: COMPARATOR
Intervention: Supportive care and chemotherapeutics (control)
Number of subjects: 182
Study 25638793 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine (MIR)
Number of subjects: 210
Study 25638793 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine (PAR)
Number of subjects: 210
Study 25638793 — intervention group
Group type: EXPERIMENTAL
Intervention: HAMD17
Number of subjects: 210
Study 25638793 — intervention group
Group type: EXPERIMENTAL
Intervention: Evans6 and Toronto7 subscales
Number of subjects: 210
Study 25638793 — intervention group
Group type: EXPERIMENTAL
Intervention: Subscales (general)
Number of subjects: 210
Study 23433061 — intervention group
Group type: EXPERIMENTAL
Intervention: e‐learning course for health promoters
Number of subjects: 280
Study 23433061 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 280
Study 21647703 — intervention group
Group type: EXPERIMENTAL
Intervention: Pan-retinal photocoagulation (PRP)
Number of subjects: 29
Study 19808388 — intervention group
Group type: EXPERIMENTAL
Intervention: RFA of RA CFAEs
Number of subjects: 85
Study 19808388 — intervention group
Group type: COMPARATOR
Intervention: No RFA of RA CFAEs
Number of subjects: 85
Study 19808388 — intervention group
Group type: EXPERIMENTAL
Intervention: After LA RFA
Number of subjects: 85
Study 19808388 — intervention group
Group type: EXPERIMENTAL
Intervention: After final procedure
Number of subjects: 85
Study 16794458 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocoa flavanols (including 4'-O-methyl-epicatechin)
Number of subjects: 0
Study 16794458 — intervention group
Group type: EXPERIMENTAL
Intervention: Flavanol-rich cocoa beverage
Number of subjects: 0
Study 16794458 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 0
Study 15609769 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate-salmeterol (100 microg/50 microg)
Number of subjects: 1910
Study 15609769 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone propionate (100 microg)
Number of subjects: 1910
Study 15609769 — intervention group
Group type: COMPARATOR
Intervention: Montelukast (10 mg)
Number of subjects: 1910
Study 11140385 — intervention group
Group type: EXPERIMENTAL
Intervention: Earrings with a surface layer consisting of 24-carat gold
Number of subjects: 60
Study 11140385 — intervention group
Group type: COMPARATOR
Intervention: Earrings with a surface layer of titanium nitride
Number of subjects: 60
Study 9286518 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% sucrose solution dripped onto enamel blocks from 0 to 8 times/day
Number of subjects: 12
Study 9286518 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride-free dentifrice used by all subjects
Number of subjects: 12
Study 9286518 — intervention group
Group type: EXPERIMENTAL
Intervention: Water fluoridated at 0.70 ppm F
Number of subjects: 12
Study 7950179 — intervention group
Group type: EXPERIMENTAL
Intervention: Jiangzhi Zhongyao Pian (JZZYP)
Number of subjects: 62
Study 7950179 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 3313776 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesalazine (5-ASA) suppositories (3 x 250 mg/day)
Number of subjects: 16
Study 3313776 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 29439307 — intervention group
Group type: EXPERIMENTAL
Intervention: UltraTENS
Number of subjects: 61
Study 29439307 — intervention group
Group type: COMPARATOR
Intervention: PhP
Number of subjects: 61
Study 28811158 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct acting antiviral therapy (DAAs)
Number of subjects: 89
Study 26256135 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga intervention
Number of subjects: 46
Study 26256135 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 46
Study 24205185 — intervention group
Group type: EXPERIMENTAL
Intervention: MVA.HIVA vaccine
Number of subjects: 48
Study 24205185 — intervention group
Group type: COMPARATOR
Intervention: EPI vaccines
Number of subjects: 48
Study 21128879 — intervention group
Group type: EXPERIMENTAL
Intervention: dalcetrapib 600 mg/day
Number of subjects: 476